Evidence map›Paper›PMID 40646119›Full record

ArticleScientific reports2025

A promising platform of hypoxia sensitive magnetosomes in hepatocellular carcinoma therapy.

Kun Deng, Jiaojiao Wang, Xia Zhou, Yuanyuan Geng, Weiquan Liu, Yiheng Zhang, Yuangang Liu, Wei Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kun Deng *State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, China Agricultural University, Beijing, 100193, China.
Jiaojiao Wang *State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, China Agricultural University, Beijing, 100193, China.
Xia Zhou *Institute of Pharmaceutical Engineering, Huaqiao University, Xiamen, 361021, China.
Yuanyuan GengState Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, China Agricultural University, Beijing, 100193, China.
Weiquan LiuState Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, China Agricultural University, Beijing, 100193, China.
Yiheng ZhangInstitute of Pharmaceutical Engineering, Huaqiao University, Xiamen, 361021, China.
Yuangang LiuInstitute of Pharmaceutical Engineering, Huaqiao University, Xiamen, 361021, China. ygliu@hqu.edu.cn.
Wei JiangState Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, China Agricultural University, Beijing, 100193, China. jiangwei01@cau.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we engineered hypoxia-responsive nanoparticles (NI-HA-BMs-DOX) comprising 2-nitroimidazole (NI), hyaluronic acid (HA), bacterial magnetosomes (BMs), and doxorubicin (DOX) for targeted drug delivery. Under tumor hypoxia, the hypoxia-sensitive NI moiety undergoes reduction to 2-aminoimidazole, inducing a transition of the nanoparticles from a hydrophobic to a hydrophilic state, thereby facilitating controlled DOX release. Cellular assays demonstrated selective DOX delivery to HepG2 hepatocellular carcinoma cells under hypoxic conditions, while exhibiting minimal cytotoxicity toward normal hepatocytes (HL-7702). NI-HA-BMs-DOX significantly enhanced tumor cytotoxicity and apoptosis by upregulating caspase-3, caspase-8, and Tp53, demonstrating superior efficacy compared to free DOX and HA-BMs-DOX. In vivo studies further confirmed the therapeutic potential of NI-HA-BMs-DOX (4 mg/kg DOX equivalent), achieving a tumor inhibition rate of 55.38%, which exceeded that of HA-BMs-DOX (43.88%) and free DOX (34.90%). These findings validate NI-HA-BMs-DOX as a promising hypoxia-targeted therapeutic platform for HCC and highlight the potential of bacterial magnetosomes in improving drug delivery strategies for cancer treatment.

Indexed as

Carcinoma, HepatocellularDoxorubicinLiver NeoplasmsMagnetosomesAnimalsApoptosisDrug Delivery SystemsHep G2 CellsHumansHyaluronic AcidMiceMice, Inbred BALB CNanoparticlesNitroimidazolesXenograft Model Antitumor AssaysDoxorubicinHyaluronic AcidNitroimidazolesAntitumor effectBacterial magnetosomesDoxorubicinHypoxia

Identifiers

PMID40646119
PMCPMC12254477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.